Notice Regarding the Mutual Termination of the Share Transfer Agreement for Crown Bioscience
JSR Corporation (Headquarters: Minato-ku, Tokyo; Representative Director, President and CEO: Tetsuro Hori; “JSR”) announces that, following discussions, the parties have agreed to terminate the share transfer agreement announced in November 2025, effective November 13, 2026. Under that agreement, JSR's group company, JSR Life Sciences, LLC, was to transfer all shares of its wholly owned subsidiary, Crown Bioscience International ("Crown Bioscience"), to Miramar Lifesciences Limited, a wholly owned subsidiary of Adicon Holdings Limited (HKEX: 9860.HK; Headquarters: Hangzhou, China; "Adicon").
The parties had been working toward completion of the share transfer. However, as the conditions precedent to closing were not expected to be satisfied within the originally anticipated timeframe, the parties have agreed to terminate the agreement by mutual agreement. The termination of the agreement will not result in any changes to Crown Bioscience's business operations or its dealings with customers and other business partners.
At this time, JSR expects the impact of this matter on its financial performance to be limited. Should any matters requiring disclosure arise in connection with this matter, JSR will promptly announce them.
